Codice QR

Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma

Background. The development of radical therapy for multiple myeloma (MM) is still a pressing problem. This progressive disease requires repeated courses of therapy using drugs without cross-resistance. The prognosis of “double refractory” MM which is resistant to key antitumor drugs, first generatio...

Descrizione completa

Salvato in:
Autori principali: Aleksei Vladilenovich Petrov, D. V. Motorin, O. S. Pokrovskaya, E. S. Urnova, M. V. Nareiko, D. V. Babenetskaya, Yu. A. Alekseeva, L. L. Girshova, L. P. Mendeleeva, A. Yu. Zaritskii
Natura: Artigo
Lingua:Russo
Pubblicazione: Practical Medicine Publishing House 2017-07-01
Serie:Клиническая онкогематология
Soggetti:
multiple myeloma
“double-refractoriness”
immunomodulating agents
pomalidomide
Accesso online:https://bloodjournal.ru/index.php/coh/article/view/440
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi